openPR Logo
Press release

Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I

07-10-2017 10:48 AM CET | Health & Medicine

Press release from: Phenex Pharmaceuticals

/ PR Agency: akampion
-- Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations --

Ludwigshafen, Germany, July 10, 2017

Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases.

“We are very pleased to see this candidate progressing into Phase I clinical testing,” comments Thomas Hoffmann, CFO of Phenex AG. “This recently achieved development milestone underlines the success of the RORgt program within the Phenex-Janssen collaboration. We can expect more revenue streams to come from similar milestones in future. We wish Janssen all the best in their development efforts.”

Dr. Claus Kremoser, CEO of Phenex, adds: “We are proud of the quality of our drug discovery approach and of the fact that we have licensed out two programs at preclinical stage to Janssen (RORgt) and Gilead (FXR), respectively, and both have born clinical candidates that are now in clinical development. Drug Discovery is more than just a process that can be rationalized and cost-trimmed for efficiency. It is an art, takes time and requires more than one close look at the details. We are glad to see that the success rate of our programs is so high. This gives us confidence that we can foster similar collaborations on other targets using different proprietary chemistry in the field of liver diseases and cancer which are our two focus areas of research now.”

About Phenex Pharmaceuticals AG:

Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a major research site in Heidelberg. The biopharmaceutical company can built on fourteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex ́ R&D activities are centered around diseases of the liver / gastrointestinal tract, as well as cancer. It is the company ́s goal to partner and outlicense drug programs in areas with major market potential to global players from the biopharmaceutical industry while pursuing own drug development in niche areas with particular high medical needs.

Visit our homepage at:

Phenex Pharmaceuticals AG
Donnersbergweg 1
D-67059 Ludwigshafen
Phone: +49-6221-65282-0
Fax: +49-6221-65282-10
Dr. Claus Kremoser
Thomas Hoffmann

Media Inquiries:
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I here

News-ID: 616374 • Views: 696

More Releases for Janssen

Antibiotics: Market Growth Stratagies (Pfizer, Janssen Pharmaceuticals, Abbott, …
Antibiotics Market Status and Outlook 2019-2025 that centers in industry upgrades, providing analytical and exclusive statistics. Worldwide market trends are analyzed using recently accessible Antibiotics data pertinent to the sum of the market businesses and their economy share. The global Antibiotics report highlights the size, share, trends, dynamics and growth, and earnings in addition to leading companies, revenue, ingestion, procedures, and innovative estimations. REQUEST SAMPLE REPORT WITH TOC: The Antibiotics industry
Chemotherapy-Induced Myelosuppression Treatment Market Analysis by 2028 | Amgen …
A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including, Development of natural product interventions for chemotherapy-induced side effects Growing implementation of radiation treatment in cancer treatment owing to the associated high success rate of chemotherapy Growing R&D investments
Global Immunosuppressant Drugs Market 2019 - Pharmacyclics, Inc., Janssen Biotec …
The Global Immunosuppressant Drugs Market 2019 - overview combining the data integration and analysis capabilities with the relevant findings, the report has predicted strong future growth of the market. The research analyst combining secondary research which involves reference to various statistical databases, relevant patent and regulatory databases and a number of internal a nd external proprietary databases. Cell Line Development Equipment report has focused on each region market
Radiation-Induced Myelosuppression Treatment Market Opportunity Analysis by 2028 …
Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years. Radiation therapy has been a significant part of cancer treatment and the
Antibiotics Market 2019 Global Analysis By Key Players – Pfizer, Janssen Pharm …
Antibiotics Market 2019 Wiseguyreports.Com adds “Antibiotics Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Report Details: This report provides in depth study of “Antibiotics Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Antibiotics Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such
Global Proton Pump Inhibitors Market Outlook 2018-2025 Pfizer, Eli Lilly, AstraZ …
A detailed market study on "Global Proton Pump Inhibitors (PPIs) Market" examines the performance of the Proton Pump Inhibitors (PPIs) market. It encloses an in-depth Research of the Proton Pump Inhibitors (PPIs) market state and the competitive landscape globally. This report analyzes the potential of Proton Pump Inhibitors (PPIs) market in the present and the future prospects from various angles in detail. The Global Proton Pump Inhibitors (PPIs) Market 2018 report